These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 30664963

  • 1. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma.
    Gomes S, Raimundo L, Soares J, Loureiro JB, Leão M, Ramos H, Monteiro MN, Lemos A, Moreira J, Pinto M, Chlapek P, Veselska R, Sousa E, Saraiva L.
    Cancer Lett; 2019 Apr 01; 446():90-102. PubMed ID: 30664963
    [Abstract] [Full Text] [Related]

  • 2. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
    Peirce SK, Findley HW.
    Int J Oncol; 2009 May 01; 34(5):1395-402. PubMed ID: 19360352
    [Abstract] [Full Text] [Related]

  • 3. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J, Guan S, Zhao Y, Yu Y, Wang Y, Shi Y, Mao X, Yang KL, Sun W, Xu X, Yi JS, Yang T, Yang J, Nuchtern JG.
    Oncotarget; 2016 Dec 13; 7(50):82757-82769. PubMed ID: 27764791
    [Abstract] [Full Text] [Related]

  • 4. In Vitro Characterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Cancer Cell Lines.
    Al-Ghabkari A, Narendran A.
    Cancer Biother Radiopharm; 2019 May 13; 34(4):252-257. PubMed ID: 30724592
    [Abstract] [Full Text] [Related]

  • 5. Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents.
    Lemos A, Gomes AS, Loureiro JB, Brandão P, Palmeira A, Pinto MMM, Saraiva L, Sousa ME.
    Molecules; 2019 May 22; 24(10):. PubMed ID: 31121972
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.
    J Natl Cancer Inst; 2009 Nov 18; 101(22):1562-74. PubMed ID: 19903807
    [Abstract] [Full Text] [Related]

  • 7. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J, Raimundo L, Pereira NA, dos Santos DJ, Pérez M, Queiroz G, Leão M, Santos MM, Saraiva L.
    Pharmacol Res; 2015 Nov 18; 95-96():42-52. PubMed ID: 25814188
    [Abstract] [Full Text] [Related]

  • 8. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
    Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone KA, Schild L, Aviles-Padilla K, Nikzad R, Zhang Y, Chakraborty R, Molenaar JJ, Vasudevan SA, Sheehan V, Kim ES, Paust S, Shohet JM, Barbieri E.
    Clin Cancer Res; 2017 Nov 01; 23(21):6629-6639. PubMed ID: 28821555
    [Abstract] [Full Text] [Related]

  • 9. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.
    Oncogene; 2007 May 24; 26(24):3473-81. PubMed ID: 17146434
    [Abstract] [Full Text] [Related]

  • 10. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M, Shi Y, Hedström E, Kogner P, Selivanova G.
    Clin Cancer Res; 2013 Sep 15; 19(18):5092-103. PubMed ID: 23864164
    [Abstract] [Full Text] [Related]

  • 11. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
    Maser T, Zagorski J, Kelly S, Ostrander A, Goodyke A, Nagulapally A, Bond J, Park Y, Saulnier Sholler G.
    Cancer Med; 2020 Nov 15; 9(21):8144-8158. PubMed ID: 33034426
    [Abstract] [Full Text] [Related]

  • 12. Aurora kinases as targets in drug-resistant neuroblastoma cells.
    Michaelis M, Selt F, Rothweiler F, Löschmann N, Nüsse B, Dirks WG, Zehner R, Cinatl J.
    PLoS One; 2014 Nov 15; 9(9):e108758. PubMed ID: 25268132
    [Abstract] [Full Text] [Related]

  • 13. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
    Leão M, Pereira C, Bisio A, Ciribilli Y, Paiva AM, Machado N, Palmeira A, Fernandes MX, Sousa E, Pinto M, Inga A, Saraiva L.
    Biochem Pharmacol; 2013 May 01; 85(9):1234-45. PubMed ID: 23428467
    [Abstract] [Full Text] [Related]

  • 14. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J, Pereira NA, Monteiro Â, Leão M, Bessa C, Dos Santos DJ, Raimundo L, Queiroz G, Bisio A, Inga A, Pereira C, Santos MM, Saraiva L.
    Eur J Pharm Sci; 2015 Jan 23; 66():138-47. PubMed ID: 25312347
    [Abstract] [Full Text] [Related]

  • 15. The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells.
    Dabiri Y, Kalman S, Gürth CM, Kim JY, Mayer V, Cheng X.
    Sci Rep; 2017 Jul 14; 7(1):5423. PubMed ID: 28710427
    [Abstract] [Full Text] [Related]

  • 16. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
    Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J, Tweddle DA.
    Oncotarget; 2015 Apr 30; 6(12):10207-21. PubMed ID: 25844600
    [Abstract] [Full Text] [Related]

  • 17. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
    Tonino SH, Mulkens CE, van Laar J, Derks IA, Suo G, Croon-de Boer F, van Oers MH, Eldering E, Wang JY, Kater AP.
    Leuk Lymphoma; 2015 Apr 30; 56(8):2439-47. PubMed ID: 25511680
    [Abstract] [Full Text] [Related]

  • 18. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J, Sakashita S, Allo G, Ludkovski O, Ng C, Shepherd FA, Tsao MS.
    J Thorac Oncol; 2015 Aug 30; 10(8):1172-80. PubMed ID: 26200271
    [Abstract] [Full Text] [Related]

  • 19. Curcumin induces apoptosis in p53-null Hep3B cells through a TAp73/DNp73-dependent pathway.
    Wang J, Xie H, Gao F, Zhao T, Yang H, Kang B.
    Tumour Biol; 2016 Mar 30; 37(3):4203-12. PubMed ID: 26490992
    [Abstract] [Full Text] [Related]

  • 20. Ribosomal proteins L11 and L5 activate TAp73 by overcoming MDM2 inhibition.
    Zhou X, Hao Q, Zhang Q, Liao JM, Ke JW, Liao P, Cao B, Lu H.
    Cell Death Differ; 2015 May 30; 22(5):755-66. PubMed ID: 25301064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.